Takeda Pharmaceuticals is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda Development Center EU (UK) is the legal entity representing Takeda in this project that involves also OSHI Health, a spin-off company of Takeda dedicated to provide a digital platform for people suffering from IBD.
Main tasks in the project
- In WP1, Takeda will act as the Industry co-lead and assist with consortium management activities.
- In WP2, Takeda will contribute to the design of the study protocols and assist with the statistical data analysis.
- In WP3, Takeda will support the device selection process.
- In WP6, Takeda will contribute their expertise in devising the operational and monitoring strategies of the clinical validation study and advise on the associated regulatory issues.
- In WP7, Takeda will provide data
